Latest news | Leukaemia Foundation - Page 2

Latest news

Leukaemia Foundation supports better access to clinical trials for all Australians

Friday, 3 May 2019

The Leukaemia Foundation says recent commitments from each major political party to support better access to clinical cancer trials are a pivotal step toward improving outcomes for Australians living with blood cancers.

The Leukaemia Foundation has welcomed the latest $100 million commitment from the Federal Government to

Read More

Federal Health Minister Greg Hunt commits to Blood Cancer Taskforce and Action Plan

Wednesday, 17 April 2019

The Leukaemia Foundation welcomes the commitment from the Federal Health Minister Greg Hunt to establish a Blood Cancer Taskforce and Action Plan.

The Blood Cancer Taskforce will work with leading clinicians, researchers and patient groups in the blood cancer community to

Read More

Leukaemia Foundation supports Labor’s $20 million blood cancer Right to Trial

Wednesday, 17 April 2019

The Leukaemia Foundation welcomes Federal Labor’s commitment of $20 million to give Australian blood cancer patients faster access to leading clinical trial drugs and therapies through a new Right to Trial program.

Leukaemia Foundation CEO Bill Petch today joined Opposition Leader Bill Shorten and Shadow Health Minister for Health and Medicare Catherine King at

Read More

South Australian researchers to develop cutting edge genetic testing

Tuesday, 16 April 2019

The Leukaemia Foundation is funding a cutting-edge diagnostic test that would help clinicians identify specific gene mutations to offer more effective, targeted treatments for Australians living with blood cancer.

The SA Genomics Haematology Malignancies Node will have the first of three tests available across Australia in six

Read More

CAR-T therapy receives Federal Government funding allowing young people with ALL to receive innovative treatment

Monday, 15 April 2019,

The Leukaemia Foundation has welcomed today’s announcement by Federal Health Minister Greg Hunt to list CAR-T therapy on the Medicare Benefits Schedule (MBS). The treatment will be for use in paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant,

Read More

Welcome commitment to reduce out-of-pocket cancer costs

Friday, 05 April 2019

The Leukaemia Foundation welcomes Federal Labor’s commitment to reducing out-of-pocket costs for cancer patients as part of a $2.3 billion funding package announced in last night’s Federal Budget reply.  

The announcement includes funding to remove out-of-pocket costs associated with diagnostic imaging, bulk-billed Medicare items for oncologists and specialist surgeons,

Read More

New PBS listing vital to Australians living with B-cell Acute Lymphoblastic Leukaemia

Thursday, 4 April 2019

The Leukaemia Foundation has welcomed news Australians living with B-cell acute lymphoblastic leukaemia (B-ALL) will have access to the drug inotuzumab ozogamicin (Besponsa®) through the Pharmaceutical Benefits Scheme (PBS) after the listing was announced in this week’s Federal Budget.

According to the Federal Government, Australians living with

Read More

New Australian facilities announced for break-through CAR-T therapy and other immunotherapy clinical trials

Tuesday, 26 March 2019

The Leukaemia Foundation welcomes the federal government $80 million investment to establish the Peter MacCallum Centre as a new base for Car-T Cell therapy and other immunotherapy clinical trials in Australia. 

The funding package would help to build 2,600 square met facilities to manufacture commercial CAR-T

Read More

Leukaemia Foundation to partner with Tour de Cure for the inaugural Life Ride

Tuesday, 26 March 2019

The Leukaemia Foundation and Tour de Cure will combine forces in 2019 to host the first Life Ride – an inspiring three-day cycling event to help fund research and find a cure for blood cancer.

The inaugural Life Ride will be held in the spectacular Margaret River region of Western Australia from Sunday,

Read More

Treatment for cutaneous T-cell lymphomas to be subsidised through broadened PBS listing

Thursday, 21 March 2019

The Leukaemia Foundation welcomes the Federal Government’s announcement that the Pharmaceutical Benefits Scheme (PBS) listing of brentuximab vedotin (Adcetris®) will be broadened to include treatment of cutaneous T-cell lymphomas (CTCL) from 1 April 2019.

CTCL is a type of non-Hodgkin lymphoma that directly attacks the body’s T-cells, a type of white

Read More

Share this page

X
X